Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/197222 
Year of Publication: 
2017
Citation: 
[Journal:] Health Economics Review [ISSN:] 2191-1991 [Volume:] 7 [Issue:] 26 [Publisher:] Springer [Place:] Heidelberg [Year:] 2017 [Pages:] 1-14
Publisher: 
Springer, Heidelberg
Abstract: 
The administration of (biologically-derived) drugs for various disease conditions involves consumption of resources that constitutes a direct monetary cost to healthcare payers and providers. An often ignored cost relates to a mismatch between patients' preferences and the mode of drug administration. The 'intangible' benefits of giving patients what they want in terms of the mode of drug delivery is seldom considered. This study aims to evaluate, in monetary terms, end-user preferences for the non-monetary attributes of different modes of drug administration using a discrete-choice experiment. It provides empirical support to the notion that there are significant benefits from developing patient-friendly approaches to drug delivery. The gross benefits per patient per unit administration is in the same order of magnitude as the savings in resource costs of administering drugs. The study argues that, as long as the underlying manufacturing science is capable, a patient-centred approach to producing drug delivery systems should be encouraged and pursued.
Subjects: 
Discrete-choice experiments
Drug administration
Manufacturing
United Kingdom
Persistent Identifier of the first edition: 
Creative Commons License: 
cc-by Logo
Document Type: 
Article

Files in This Item:
File
Size
962.43 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.